Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - Poll - MDSpire

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  • By

  • Christen M. Dillard

  • Hans Lee

  • Nilesh Kalariya

  • Naveen Subramanian

  • Oren Pasvolsky

  • Christopher Ferreri

  • Mahmoud Gaballa

  • Sheeba K. Thomas

  • Donna M. Weber

  • Melody Becnel

  • Gregory Kaufman

  • Muzaffar Qazilbash

  • Robert Z. Orlowski

  • Michelle A. T. Hildebrandt

  • Krina K. Patel

  • April 13, 2026

  • 0 min

Share

Original Source(s)

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  • by Christen M. Dillard, Hans Lee, Nilesh Kalariya, Naveen Subramanian, Oren Pasvolsky, Christopher Ferreri, Mahmoud Gaballa, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Gregory Kaufman, Muzaffar Qazilbash, Robert Z. Orlowski, Michelle A. T. Hildebrandt, Krina K. Patel

  • April 13, 2026

Related Content

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min